Latent-Y
Share
Latent-Y
AI agent for autonomous antibody design from text. Generates lab-validated candidates and accelerates weeks of research into just hours.
General Information about Latent-Y
Latent-Y is an advanced artificial intelligence agent developed by Latent Labs for autonomous drug design using natural language instructions. This tool allows researchers and biotechnology teams to generate high-affinity antibodies and peptides without the need for constant manual intervention, transforming complex therapeutic targets into lab-ready candidates in a matter of hours. Its primary function is to act as a force multiplier in the drug discovery process, compressing workflows that traditionally require weeks of expert labor into an automated and efficient process.
The underlying technology for this application is the Latent-X2 model, a frontier architecture specialized in designing antibodies with developability properties similar to real-world drugs. Latent-Y utilizes expert-level biological reasoning to navigate biological databases, bioinformatics tools, and external scientific publications. The user only needs to enter a text prompt specifying the design goals and constraints. From there, the AI autonomously manages target analysis, epitope selection, and computational validation, producing nanobody and mini-protein sequences with lab-validated affinities.
Key functional capabilities and practical benefits include:
- Epitope discovery: Identifies specific binding sites based on the desired mechanism of action or functional constraints.
- Cross-species binder design: Generates antibodies that bind to homologous targets (e.g., human and cynomolgus), facilitating translational studies toward clinical trials.
- Publication-based design: The ability to process scientific papers in PDF format, extract relevant targets, and design candidates based on published evidence.
- Parallel campaign execution: Enables a single researcher to manage multiple design programs simultaneously, scaling the exploration of therapeutic opportunities.
- Flexible autonomy: Can operate independently from end to end or allow for human intervention at every stage to review decisions and suggestions.
Using Latent-Y represents a drastic acceleration in the computational stages of biological development. According to technical data, experts using the tool complete design campaigns up to 56 times faster than through conventional methods. Additionally, it offers total transparency by logging every design decision, allowing scientists to evaluate and build upon the AI's reasoning. It is a robust solution for pharmaceutical organizations looking to optimize de novo antibody design and macrocyclic peptides with precision reaching single-digit nanomolar affinities.
Features and Use Cases of Latent-Y
How Latent-Y Works
Frequently Asked Questions about Latent-Y
What exactly is Latent-Y and what is its primary function?
Latent-Y is an artificial intelligence agent designed for the autonomous creation of antibodies from text-based instructions, condensing weeks of expert work into just a few hours.
What is the difference between Latent-Y and the Latent-X2 model?
Latent-X2 is the underlying generative model that designs the molecules, whereas Latent-Y acts as an expert agent that utilizes that model to manage the entire research workflow autonomously.
Can Latent-Y create designs based on existing scientific publications?
Yes, the tool is capable of processing scientific papers to identify targets and epitopes, reason through the mechanism of action, and generate validated candidates without the need for manual intervention.
What level of acceleration does Latent-Y provide to drug discovery teams?
User studies demonstrate that researchers using this tool complete their design campaigns 56 times faster than they would working independently.
Have Latent-Y’s results been validated in actual laboratory experiments?
The tool has generated lab-confirmed binders for six out of nine attempted targets, achieving binding affinities in the single-digit nanomolar range.
Does a human need to oversee every step of a Latent-Y campaign?
It is not strictly necessary, as the system can operate fully autonomously; however, it offers the option to pause the process at each stage so scientists can review summaries and recommendations.
What types of design modalities does the Latent-Y platform support?
The agent’s architecture currently supports campaigns for designing single-domain antibodies (known as VHHs), as well as macrocyclic peptides and mini-binders.
How can interested organizations request access to Latent-Y?
Access is limited to select partners, who can apply through the official Latent Labs platform portal or by contacting the partnerships department via email.
Does Latent-Y replace the work of expert scientists and researchers?
It is not intended to replace professionals but rather to serve as a force multiplier, allowing a single researcher to manage multiple design campaigns simultaneously while maintaining full control.
What kind of biological information and tools does Latent-Y use for reasoning?
The agent operates in an environment equipped with access to bioinformatics tools, biological databases, and external publications, allowing it to apply expert reasoning to every design decision.
Latent-Y Pricing
Partner Access (Early Access)
Pricing is not publicly available; please visit the official website to request early access through the platform.
Autonomous de novo antibody design via text prompts.
Execute multiple design campaigns in parallel.
Access to bioinformatics tools, biological databases, and external publications.
Expert-level biological reasoning for epitope identification and target analysis.
Flexible autonomy workflows (fully autonomous or human-in-the-loop).
Support for VHH, macrocyclic peptide, and mini-binder design.
Access restrictions apply subject to compliance with EU and UK international sanctions lists.
Enterprise Deployment
Pricing is not disclosed in the available information; please visit the official website to obtain a custom quote for corporate partners.
Cloud-based access options.
Private deployment options for large organizations.
Full integration with the Latent Labs platform utilizing the Latent-X2 model.
Capacity to process complex therapeutic targets at industrial scale.
Latent-Y Screenshots
